Looking to publish in Cancer Biology & Medicine? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowCancer Biology & Medicine is dedicated to reporting the latest advances in cancer research around the world by presenting high quality articles, especially on translational cancer research, to bridge the gap between bench and bedside. The journal promotes academic exchange in cancer between China and the rest of the world and covers topics including cancer genetics, cancer and stem cell biology, molecular and clinical immunology, cancer prevention and epidemiology, cancer biomarkers, radiation oncology, oncology clinical trials, mechanisms of drug sensitivity and resistance, targeted therapy and immunotherapy, and multidisciplinary treatment and personalized medicine.
Looking to publish in Cancer Biology & Medicine? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Cancer Biology & Medicine accepts the following article types. Click on an article type to view submission instructions.
Original Article
Review
Minireview
Letter To The Editor
Practice Guideline
Recent Publications
Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH)
Lisha Shen, Dongqing Lv, Ke-Jing Tang, Jun Zhao, Dan Zhu, Yanqiu Zhao, Ke Wang, Yan Wang, Zhigang Cai, Ligang Xing, Ke Xie, Jiuwei Cui, Lin Mu, Chao Cao, Liren Ding, Peifeng Chen, Jun Liang, Yongmin Ding, Liqin Lu, Jiliang Zhang, Xinmin Yu, Li Chen, Jing Zheng, Jianya Zhou, Jianying Zhou
Treatment implications of T cell DNA damage in anti-tumor immunity
Xiaofei Jiao, Yiyang Shen, Yixuan Tang, Jiahao Liu, Qinglei Gao
Microbial reprogramming of immunogenic cell death: a new paradigm in tumor immunotherapy
Yilin Li, Huiyue Zhang, Yun Feng, Kun Fang, Yue Wang, Yuhang Zhou, Tao Sun, Junnan Xu
HBx-mediated GPT2 suppression promotes liver cancer development by downregulating ADH1A
Hongjuan You, Xing Wang, Ruyu Liu, Yuxin Wang, Huanyang Zhang, Lihong Ma, Ensi Bao, Yujie Zhong, Xiangye Liu, Delong Kong, Xiucheng Pan, Xiaocui Li, Suping Qin, Kuiyang Zheng, Chen Li, Renxian Tang, Fanyun Kong
CAMK2D isoform 15 facilitates gefitinib resistance <italic>via</italic> AKT phosphorylation in lung adenocarcinoma
Lingmei Li, Danyang Ren, Yutian Wang, Jiaojiao Zhang, Chenhui Yan, Tongyuan Qu, Ruimin He, Wenshuai Zhang, Wanghao Li, Ningrui Feng, Yalei Wang, Yuhong Guo, Lisha Qi, Lu Cao, Qianru Guo, Qiang Zhao, Zhaoxiang Ye, Wenfeng Cao
Frequently asked questions
How long does it take to publish?
Revised manuscripts should be submitted within two months after authors receive reviewers' comments. The journal generally allows only one round of revision.
Reformat to Cancer Biology & Medicine using Livewrite PremiumIs a cover letter required?
A cover letter is required for each submission. It should include the manuscript title, a brief summary of significant findings, a statement of exclusive submission and no plagiarism or other misconduct, a statement that all authors approved the submission, the corresponding author's contact information, and suggested reviewer inclusions or exclusions.
Reformat to Cancer Biology & Medicine using Livewrite PremiumWhat are the publication costs?
Most journals are Gold Open Access. Article processing charges may be required only after a manuscript is editorially accepted and before publication; journal-specific APCs vary by journal.
Reformat to Cancer Biology & Medicine using Livewrite Premium